Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 15/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.30 |
| ▸ | CHRNG | P07510 | 1/20 | 0.30 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CHRND | Q07001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13104662 | 0.96 | PDK2 (0.34) | PDK2LPLLIPGSLC6A2SLC6A4 | |
| SCHEMBL17180558 | 0.95 | PDK2 (0.33) | PDK2LPLLIPGSLC6A2SLC6A4 | |
| SCHEMBL13104644 | 0.95 | LPL (0.35) | PDK2LPLLIPGSLC6A2SLC6A4 | |
| SCHEMBL18492717 | 0.93 | PDK2 (0.35) | PDK2SLC6A2SLC6A4SLC6A3CHRNA1 | |
| SCHEMBL13878129 | 0.93 | PDK2 (0.36) | PDK2LPLLIPGSLC6A2SLC6A4 | |
| SCHEMBL13153091 | 0.93 | PDK2 (0.36) | PDK2LPLLIPGSLC6A2SLC6A4 | |
| SCHEMBL24905384 | 0.92 | LPL (0.38) | PDK2LPLLIPGSLC6A2SLC6A4 | |
| SCHEMBL20466603 | 0.92 | LPL (0.38) | PDK2LPLLIPGSLC6A2SLC6A4 | |
| SCHEMBL13104673 | 0.92 | PDK2 (0.38) | PDK2SLC6A2SLC6A4 | |
| SCHEMBL13104660 | 0.92 | PDK2 (0.32) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807277-B2 | Amine compound and organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20080124573-A1 | AMINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124573-A1 | AMINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE | AHR, HTR1D, TPH1 | PDK2 3523/4885LPL 2026/4885LIPG 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.